HROW Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

88.90M

+33.02%

0.363

+51.19%

68.68M

+43.59%

-0.038

-92.33%

89.91M

+41.05%

0.288

+121.79%

Estimates Revision

The market is revising Downward the revenue expectations for Harrow, Inc. (HROW) for FY2025, with the revenue forecasts being adjusted by -3.7% over the past three months. During the same period, the stock price has changed by 6.56%.

Revenue Estimates for FY2025

Revise Downward

-3.7%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-73.27%

In Past 3 Month

Stock Price

Go Up

+6.56%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast HROW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HROW is 72.67 USD with a low forecast of 63.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 45.700

Low

63.00

Averages

72.67

High

94.00

Current: 45.700

Low

63.00

Averages

72.67

High

94.00

Ladenburg

Jeffrey Cohen

Buy

maintain

$64 -> $66

2025-11-12

Reason

Ladenburg

Jeffrey Cohen

Price Target

$64 -> $66

2025-11-12

maintain

Buy

Reason

Ladenburg analyst Jeffrey Cohen raised the firm's price target on Harrow to $66 from $64 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report.

H.C. Wainwright

Buy

maintain

$64 -> $69

2025-11-12

Reason

H.C. Wainwright

Price Target

$64 -> $69

2025-11-12

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Harrow to $69 from $64 and keeps a Buy rating on the shares. The company reported a "robust" Q3 and its growth momentum for Vevye and Iheezo should continue in 2026, the analyst tells investors in a research note. The firm also believes Harrow's new product launches in 2026 should further drive sales growth.

Cantor Fitzgerald

NULL -> Overweight

maintain

$76 -> $94

2025-11-11

Reason

Cantor Fitzgerald

Price Target

$76 -> $94

2025-11-11

maintain

NULL -> Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Harrow to $94 from $76 and keeps an Overweight rating on the shares.

Cantor Fitzgerald

Overweight

maintain

$76 -> $94

2025-11-11

Reason

Cantor Fitzgerald

Price Target

$76 -> $94

2025-11-11

maintain

Overweight

Reason

As previously reported, Cantor Fitzgerald raised the firm's price target on Harrow to $94 from $76 and keeps an Overweight rating on the shares following quarterly results. The firm now models $29M Vevye revenues in Q4, which would mean FY25 Vevye revenue would fall short of over $100M target/guidance by $8M -- not a huge deal, Cantor says, but increases pressure on 2026 where new insurance coverage and continued market share growth need to be matched by proportional revenue growth.

B. Riley

Buy

maintain

$70 -> $74

2025-10-01

Reason

B. Riley

Price Target

$70 -> $74

2025-10-01

maintain

Buy

Reason

B. Riley raised the firm's price target on Harrow to $74 from $70 and keeps a Buy rating on the shares following the analyst day. The firm says the company's pipeline portfolio and commercial roadmap up its confidence in a bullish long-term revenue and margin expansion thesis for Harrow.

Lake Street

Thomas Flaten

Buy

maintain

$42 -> $70

2025-09-29

Reason

Lake Street

Thomas Flaten

Price Target

$42 -> $70

2025-09-29

maintain

Buy

Reason

Lake Street analyst Thomas Flaten raised the firm's price target on Harrow to $70 from $42 and keeps a Buy rating on the shares. The company's investor day on Friday reinforced the firm's confidence in the company's ability to scale its business to $250M-plus in quarterly revenue by Q4 of 2027, the analyst tells investors. "It is hard to bet against success and Harrow has had plenty of it," adds the firm, which would remain buyers of the Harrow shares.

Valuation Metrics

The current forward P/E ratio for Harrow Inc (HROW.O) is 44.27, compared to its 5-year average forward P/E of 75.47. For a more detailed relative valuation and DCF analysis to assess Harrow Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

75.47

Current PE

44.27

Overvalued PE

344.08

Undervalued PE

-193.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

14.82

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

19.51

Undervalued EV/EBITDA

10.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.36

Current PS

0.00

Overvalued PS

4.56

Undervalued PS

2.16

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 135.73% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 135.73% over the last month.

Sold

Bought

HROW News & Events

Events Timeline

No data

News

8.0

12-12NASDAQ.COM

Significant Friday Options Trading: HROW, EWTX, RBLX

1.0

11-24Newsfilter

Harrow to Participate in Two Investor Conferences Focused on Ophthalmic Management

6.0

11-12Benzinga

HC Wainwright & Co. Reaffirms Buy Rating on Harrow, Increases Price Target to $69

People Also Watch

Frequently Asked Questions

What is Harrow Inc (HROW) stock price today?

The current price of HROW is 45.7 USD — it has decreased -2.89 % in the last trading day.

What is Harrow Inc (HROW)'s business?

Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

What is the price predicton of HROW Stock?

What is Harrow Inc (HROW)'s revenue for the last quarter?

Harrow Inc revenue for the last quarter amounts to 71.64M USD, increased 45.44 % YoY.

What is Harrow Inc (HROW)'s earnings per share (EPS) for the last quarter?

Harrow Inc. EPS for the last quarter amounts to 0.03 USD, decreased -125.00 % YoY.

What changes have occurred in the market's expectations for Harrow Inc (HROW)'s fundamentals?

How many employees does Harrow Inc (HROW). have?

Harrow Inc (HROW) has 382 emplpoyees as of December 16 2025.

What is Harrow Inc (HROW) market cap?

Today HROW has the market capitalization of 1.69B USD.